Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EPS (Weighted Average and Diluted) (2019 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.37 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 45.59% to -$0.37 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.44 through Dec 2025, up 118.64% year-over-year, with the annual reading at -$0.33 for FY2025, 86.02% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.37 at Whitehawk Therapeutics, down from -$0.26 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $6.96 in Q4 2021, with the low at -$9.17 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.52, with a median of -$0.6 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 13261.66% in 2021, then surged 369.12% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $6.96 in 2021, then tumbled by 106.9% to -$0.48 in 2022, then decreased by 25.0% to -$0.6 in 2023, then fell by 13.33% to -$0.68 in 2024, then surged by 45.59% to -$0.37 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.37, -$0.26, and -$0.76 for Q4 2025, Q3 2025, and Q2 2025 respectively.